Nycomed issues profit warning as US prices tumble
This article was originally published in Clinica
An intensification of the US contrast media price war has prompted Nycomed to issue a warning that full-year profits are likely to shrink by almost 20%. The demerged pharmaceutical and diagnostic arm of the Norwegian Hafslund Nycomed group expects 1996 profits to be "closer to the 1994 than the 1995 level". Nycomed Imaging reported operating profits of NKr 2,329 million ($353 million) for 1995, up 39.6% on the previous year (see Clinica No 693, p 9).
You may also be interested in...
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.
Metabesity is a complex issue that will require a multi-disciplinary approach, concerted effort and clear regulatory pathway to achieve solutions.